OBJECTIVE:Patients with bipolar disorder are at increased risk of weight gain, which in turn increases the risk for somatic disease and nonadherence to maintenance therapy. Therefore, interventions addressing weight gain are expedient for the management of this disorder. We set out to evaluate the effects of a lifestyle intervention on body mass index (BMI) and cardiovascular and metabolic parameters in patients with bipolar disorder undergoing mood-stabilizing pharmacologic treatment. METHOD: Fifty outpatients with bipolar disorder undergoing mood-stabilizing treatment participated in arandomized controlled trial (waiting control group: n = 24 and multimodal lifestyle intervention group: n = 26). Groups consisted of 2 cohorts (cohort 1: March 2005-February 2006; cohort 2: September 2005-August 2006). The intervention lasted 5 months and consisted of 11 group sessions and weekly fitness training. BMI and body weight as well as cardiovascular and metabolic parameters were determined at 3 assessment points: at pretreatment baseline, at 5 months (end of treatment), and at 11 months (6-month follow-up). RESULTS: Intention-to-treat analyses showed that the intervention significantly reduced BMI over time (P = .03), with significant and stable mean differences in BMI change between groups of 0.7 kg/m² (95% CI, 0.2-1.3) at 5 months and 0.8 kg/m² (95% CI, 0.1-1.6) at 11 months' follow-up assessment. The lifestyle intervention had no significant effect on cardiovascular and metabolic parameters (all nonsignificant). The BMI reduction was only seen in female patients (P = .003). CONCLUSIONS: BMI in patients with bipolar disorder can be reduced with a long-lasting effect by a multimodal lifestyle intervention. However, this effect was only seen in female participants, indicating the need for gender-specific interventions. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00980863.
RCT Entities:
OBJECTIVE:Patients with bipolar disorder are at increased risk of weight gain, which in turn increases the risk for somatic disease and nonadherence to maintenance therapy. Therefore, interventions addressing weight gain are expedient for the management of this disorder. We set out to evaluate the effects of a lifestyle intervention on body mass index (BMI) and cardiovascular and metabolic parameters in patients with bipolar disorder undergoing mood-stabilizing pharmacologic treatment. METHOD: Fifty outpatients with bipolar disorder undergoing mood-stabilizing treatment participated in a randomized controlled trial (waiting control group: n = 24 and multimodal lifestyle intervention group: n = 26). Groups consisted of 2 cohorts (cohort 1: March 2005-February 2006; cohort 2: September 2005-August 2006). The intervention lasted 5 months and consisted of 11 group sessions and weekly fitness training. BMI and body weight as well as cardiovascular and metabolic parameters were determined at 3 assessment points: at pretreatment baseline, at 5 months (end of treatment), and at 11 months (6-month follow-up). RESULTS: Intention-to-treat analyses showed that the intervention significantly reduced BMI over time (P = .03), with significant and stable mean differences in BMI change between groups of 0.7 kg/m² (95% CI, 0.2-1.3) at 5 months and 0.8 kg/m² (95% CI, 0.1-1.6) at 11 months' follow-up assessment. The lifestyle intervention had no significant effect on cardiovascular and metabolic parameters (all nonsignificant). The BMI reduction was only seen in female patients (P = .003). CONCLUSIONS: BMI in patients with bipolar disorder can be reduced with a long-lasting effect by a multimodal lifestyle intervention. However, this effect was only seen in female participants, indicating the need for gender-specific interventions. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00980863.
Authors: Mario Alvarez-Jiménez; Sarah E Hetrick; César González-Blanch; John F Gleeson; Patrick D McGorry Journal: Br J Psychiatry Date: 2008-08 Impact factor: 9.319
Authors: Mario Alvarez-Jiménez; Obdulia Martínez-García; Rocío Pérez-Iglesias; Mari Luz Ramírez; Jose Luis Vázquez-Barquero; Benedicto Crespo-Facorro Journal: Schizophr Res Date: 2010-01 Impact factor: 4.939
Authors: K R Fontaine; M Heo; E P Harrigan; C L Shear; M Lakshminarayanan; D E Casey; D B Allison Journal: Psychiatry Res Date: 2001-04-15 Impact factor: 3.222
Authors: Susan L McElroy; Mark A Frye; Trisha Suppes; Dawn Dhavale; Paul E Keck; Gabriele S Leverich; Lori Altshuler; Kirk D Denicoff; Willem A Nolen; Ralph Kupka; Heinz Grunze; Jorg Walden; Robert M Post Journal: J Clin Psychiatry Date: 2002-03 Impact factor: 4.384
Authors: M Mauri; M Simoncini; S Castrogiovanni; N Iovieno; D Cecconi; G Dell'Agnello; M Quadrigli; A Rossi; P Donda; A Fagiolini; G B Cassano Journal: Pharmacopsychiatry Date: 2008-01 Impact factor: 5.788
Authors: C Torrent; B Amann; J Sánchez-Moreno; F Colom; M Reinares; M Comes; A R Rosa; J Scott; E Vieta Journal: Acta Psychiatr Scand Date: 2008-05-22 Impact factor: 6.392
Authors: Susan L McElroy; Mark A Frye; Lori L Altshuler; Trisha Suppes; Gerhard Hellemann; David Black; Jim Mintz; Ralph Kupka; Willem Nolen; Gabriele S Leverich; Kirk D Denicoff; Robert M Post; Paul E Keck Journal: Bipolar Disord Date: 2007-06 Impact factor: 6.744
Authors: Isabelle E Bauer; Juan F Gálvez; Jane E Hamilton; Vicent Balanzá-Martínez; Giovana B Zunta-Soares; Jair C Soares; Thomas D Meyer Journal: J Psychiatr Res Date: 2015-12-12 Impact factor: 4.791
Authors: Johanna Taylor; Brendon Stubbs; Catherine Hewitt; Ramzi A Ajjan; Sarah L Alderson; Simon Gilbody; Richard I G Holt; Prakash Hosali; Tom Hughes; Tarron Kayalackakom; Ian Kellar; Helen Lewis; Neda Mahmoodi; Kirstine McDermid; Robert D Smith; Judy M Wright; Najma Siddiqi Journal: PLoS One Date: 2017-01-05 Impact factor: 3.240
Authors: Caterina Del Mar Bonnín; María Reinares; Anabel Martínez-Arán; Esther Jiménez; Jose Sánchez-Moreno; Brisa Solé; Laura Montejo; Eduard Vieta Journal: Int J Neuropsychopharmacol Date: 2019-08-01 Impact factor: 5.176